2007: Biologic Therapies in RA: Clinical Aspects
Search or Browse by Day

Biologic Therapies in RA: Clinical Aspects

725
B-Cell Activity in Synovium Predicts Responsiveness to Rituximab in Patients with Refractory Rheumatoid Arhtritis
726
Efficacy and Safety of Etanercept 100 mg in Patients with Rheumatoid Arthritis Who Are Suboptimal Responders to Etanercept 50 mg
727
Response to Second or Third Tnf-inhibitor in Rheumatoid Arthritis: Results from an Observational Study
728
Persistence of Clinical Benefit in Rheumatoid Arthritis After Discontinuation of TNF-Inhibitor Therapy: Analysis from the CORRONA Database
729
The Prevalence, Incidence, and Effect of Anti-Tumor Necrosis Factor (TNF) on Work Disability in Rheumatoid Arthritis
730
Pregnancy Outcome after Exposure to Biologics: Results from the German Biologics Register RABBIT
See more of: ACR Abstract Submission ACR Concurrent Abstract Session
<< Previous Session Level | Next Session Level >>